Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 6/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883169 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL11982042 | 0.94 | HPGDS (0.48) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL12147920 | 0.94 | HPGDS (0.48) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL16907949 | 0.91 | HPGDS (0.42) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL17249887 | 0.91 | HPGDS (0.42) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL1293419 | 0.91 | HPGDS (0.42) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL1293420 | 0.91 | HPGDS (0.42) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15368521 | 0.88 | HPGDS (0.44) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL9980354 | 0.88 | HPGDS (0.44) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL12160048 | 0.87 | HPGDS (0.44) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9079887-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2852587-A1 | ANTIVIRAL COMPOUNDS WITH AN IMIDAZOLE - BIPHENYL - IMIDAZOLE CORE | Gilead Sciences, Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2013173492-A1 | ANTIVIRAL COMPOUNDS WITH AN IMIDAZOLE - BIPHENYL - IMIDAZOLE CORE | GILEAD SCIENCES, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130309195-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-11-21 | — | — | US | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013095275-A1 | NOVEL HEPATITIS C VIRUS INHIBITORS | MEDIVIR AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HPGDS 2361/4885CYP3A4 1770/4885CYP2C9 3296/4885 |
| US-20130309195-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HPGDS 2361/4885CYP3A4 1770/4885CYP2C9 3296/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | HPGDS 2361/4885CYP3A4 1770/4885CYP2C9 3296/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HPGDS 2361/4885CYP3A4 1770/4885CYP2C9 3296/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HPGDS 2361/4885CYP3A4 1770/4885CYP2C9 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.